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Background: Membrane vesicles released by neoplastic cells into extracellular medium contain potential of
carrying arrays of oncogenic molecules including proteins and microRNAs (miRNA). Extracellular (exosome-like)
vesicles play a major role in cell-to-cell communication. Thus, the characterization of proteins and miRNAs of
exosome-like vesicles is imperative in clarifying intercellular signaling as well as identifying disease markers.
Methods: Exosome-like vesicles were isolated using gradient centrifugation from MCF-7 and MDA-MB 231 cultures.
Proteomic profiling of vesicles using liquid chromatography-mass spectrometry (LC-MS/MS) revealed different protein
profiles of exosome-like vesicles derived from MCF-7 cells (MCF-Exo) than those from MDA-MB 231 cells (MDA-Exo).
Results: The protein database search has identified 88 proteins in MDA-Exo and 59 proteins from MCF-Exo. Analysis
showed that among all, 27 proteins were common between the two exosome-like vesicle types. Additionally, MDA-Exo
contains a higher amount of matrix-metalloproteinases, which might be linked to the enhanced metastatic property of
MDA-MB 231 cells. In addition, microarray analysis identified several oncogenic miRNA between the two types vesicles.
Conclusions: Identification of the oncogenic factors in exosome-like vesicles is important since such vesicles could
convey signals to non-malignant cells and could have an implication in tumor progression and metastasis.
Keywords: Breast cancer, Extracellular vesicles, Exosome, Liquid chromatography-mass spectrometry (LC-MS/MS),
microRNABackground
Exosome-like vesicles are among small membranous
extracellular vesicles (40–100 nm diameter) that are re-
leased in extracellular space [1,2]. In addition to tumor
cells, the exosome-like vesicles are produced by various
non malignant cell types including reticulocytes, intestinal
epithelial cells, and hematopoietic cells [3]. Exosome-like
vesicles are also present in body fluids such as synovial
fluid, saliva, urine, semen, breast milk, and blood [4-9].
These vesicles have gained much attention for their im-
portant role in intercellular communication [3,10]. Struc-
turally, these vesicles consist of a lipid bi-layer membrane* Correspondence: rizadpan@tulane.edu
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stated.similar to the cellular membrane, proteins including
host specific proteins, mRNA, and microRNA (miRNA).
Exosome-like vesicles, by transferring their content can
affect various cell types [11,12]. The growing interest in
the characterization of exosome-like vesicles in cancer re-
search arises from their potential role in carrying a large
array of oncogenic elements released by malignant cells
such as oncogenic proteins and miRNAs. Such oncogenic
proteins and miRNAs can traverse the tumor microenvir-
onment and can be taken up by recipient non-malignant
cells; this can result in the transfer of oncogenic activity
[13]. For example, it has been shown that transcripts de-
rived from glioma cells can be expressed in human brain
microvascular endothelial cells upon their exosome trans-
fer [14]. In addition to the unique signature of miRNAa in
cancer cells, the oncogenic role of miRNAs has been re-
ported in several cancers; notable examples include, the
role of miRNA-155 (mir-155) in apoptosis, differentiation,
angiogenesis, proliferation and epithelial-mesenchymalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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ported that the extracellular vesicles derived from two
breast cancer cell lines, MCF-7 and 8701-BC, carry several
antigens including those expressed on the cell surface
such as members of integrin family, tumor associated anti-
gens, HLA class I molecules, matrix metalloproteinase-9,
and tissue inhibitors of metalloproteinase-1 [16]. In
addition, the experimental evidences show that at least a
number of tumor markers found in the blood circulation
of breast cancer patients might be carried by extracellular
vesicles [16,17]. Thus, biomarker research in breast cancer
could gain great benefits from further characterization of
these vesicles. In the field of breast cancer research, al-
though the MCF-7 and MDA-MB 231 cell lines have been
widely studied and characterized, there is no study analyz-
ing miRNA and proteomics in their exosome-like vesicles.
In this study, we report the characterization of
exosome-like vesicles from serum free culture medias of
MCF-7 and MDA-MB 231 cell lines. The two types of
exosome-like vesicles were profiled for their protein and
miRNA contents. These cell lines have been shown to
shed vesicles in serum-deprived media [18], thus allow-
ing the collecting of uncontaminated vesicles in fetal bo-
vine serum [19]. The results of this study showed a
distinctive profile of the exosome-like vesicles, which
could be interfering with cancer progression.Methods
Cell culture and isolation of extra cellular vesicles
For the isolation of exosome-like vesicles from the two
breast cancer cell lines, culture supernatants from MCF7
and MDA-MB231 cells in serum deprived DMEM media
(original cell density 1×106 cells/ml) were harvested.
Then the exosome-like vesicles were isolated as de-
scribed previously with minor modifications [20]. The
culture supernatants (250 ml) were centrifuged at 300 g
for 10 minutes and then at 1,200 g for 10 minutes to
eliminate cells and debris. The cell-free supernatants
were clarified through a 0.2 μm filter to reduce the
number of contaminating large vesicles shed from
the plasma membrane. The supernatants were ultra-
centrifuged at 100,000 g for 60 minutes at 4°C
(SW41Ti, Beckman Instruments, Fullerton CA). The
pellets were resuspended in 3.6 ml PBS. Then, the ves-
icles were further purified using gradient centrifugation
on 30% sucrose/D2O density cushion in 100,000 g
ultracentrifugation (4°C for 60 minutes). A 700-μl vol-
ume of the cushion layer was collected and pelleted at
100,000 × g for 60 minutes. The pellets were washed
twice with PBS, resuspended in 250 μl PBS, and stored
at −80°C. Vesicular protein was measured by the Brad-
ford assay with the Bio-Rad Protein Assay Reagent
(BioRad Laboratories).Electron microscopy (EM)
EM imaging of vesicle preparations was performed as
previously described [10], with some modifications.
Briefly, vesicles (about 2 μg protein) were fixed in 1%
glutaraldehyde and then layered and dried on formvar-
coated 200 mesh copper grids (Polysciences, Inc. PA,
USA). Grids were then stained 1% uranylacetate in
water. Imaging took place at an accelerated voltage of
200 kV using a Tecnai G2 F30 TWIN, which is a
300 kV/FEG Transmission Electron Microscope.
Protein analysis using LC-MS/MS
The exosome-like vesicles (n = 3/exosome type) were re-
suspended in 100 μl of PBS, 2 μl triton X-100, and 5 μl phe-
nylmethylsulfonyl fluoride with vortexing to dissolve the
vesicles. The insoluble fraction was pelleted by centrifuga-
tion 20,000 g. The insoluble fraction was acetone precipi-
tated at −20°C and digested in-gel with 200 ng modified
trypsin (sequencing grade, Promega) for 18 hours at 37°C.
Resulting peptides were analyzed by LC-MS/MS on an
Orbitrap-XL mass spectrometer (Thermo Scientific, Wal-
tham MA). Proteins were identified by database searching
of the fragment spectra against the SwissProt (EBI) protein
database using Mascot (v 2.3, Matrix Science, London,
UK). Typical search settings were: mass tolerances, 10 ppm
precursor, 0.8d fragments; variable modifications, and me-
thionine sulfoxide, pyro-glutamate formation; up to 2
missed cleavages. The MS/MS spectra were then searched
against the NCBI human reference sequence database with
the search program MASCOT, a mass spectral search algo-
rithm that uses mass spectrometry data to identify proteins
from primary sequence databases. (Matrix Science, Boston,
MA). The identified peptide features were matched to a ref-
erence database and were scored according to the probabil-
ity of an overlap between the peptide feature and the
database peptides resulting in a ranked list of possible pep-
tide. This analysis generated ion scores [ions score = 10*Log
(P), where P is the probability that the observed match is a
random event] for each peptide feature. Individual ions
scores > 38 indicate identity or extensive homology
(p < 0.05) were considered.
Western blot analysis
Exosome-like vesicles were lysed in 40 μL of lysis buffer
(Promega) containing 1 μL of proteinase inhibitor cocktail
(Sigma). The total protein concentration was measured
using a Bradford assay containing Coomassie Plus protein
reagent (Bio-Rad Laboratories) according to the manufac-
turer’s specifications. Equivalent amounts of total lysate
were subjected to SDS-PAGE using 10% polyacrylamide
gels. Proteins were electroblotted to polyvinylidene difluor-
ide membrane (Millipore). The membranes were then
blocked and incubated in anti-Annexin A2 (rabbit poly-
clonal; Abcam), Alpha-enolase (mouse monoclonal; Santa
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EpCAM (mouse monoclonal; Abcam). Alkaline phosphat-
ase–conjugated anti-mouse or anti-rabbit IgGs were used
as secondary antibodies (Bio-Rad) for detection. Then the
membranes were incubated with Western Blotting
Detection Reagents (Bio-Rad) according to the manu-
facturer’s instructions and exposed to autoradiography
film.
miRNA isolation, profiling, and microarray data analysis
RNA was isolated from exosome-like vesicles using the
mirVana miRNA Isolation Kit (Ambion). Then the RNA
samples were quality-checked via the Agilent 2100 Bioana-
lyzer platform (Agilent Technologies). The results of the
Bioanalyzer run were visualized in a gel image and using
the Agilent 2100 Bioanalyzer expert software, the RNA In-
tegrity Number (RIN) was evaluated. This checks the integ-
rity and overall quality of total RNA samples. The samples
with RIN number of >6 were selected for miRNA
microarray experiments [21]. The microarray data analysis
was performed as published previously [22]. Briefly,A
B
C
Figure 1 Characterization of morphology and protein content of exos
using uranyl acetate and viewed by electron microscopy. Inside images are w
peptide targets exclusively expressed in MCF-Exo or (C) MDA-Exo. The peptid
probability of an overlap between the peptide feature and Mascot database (normalization and calculations of sample versus Universal
Reference ratios were performed with miRXploreR software
(Miltenyi Biotec) according to the calibration oligonucleo-
tide method (the median Cy5/Cy3 signal intensity ratio of
the spiked in miRcontrol calibration-oligos served as refer-
ence values). Subsequently, re-ratios between MDA-Exo
samples relative to the in silico pooled reference MCF7-Exo
were generated by multiplying each signal ratio of sample
MDA-Exo with the reciprocal value of the miRNA signal
ratio of the pooled MCF7-Exo samples. A p-value indicat-
ing the reliability of the re-ratio value was calculated for
each miRNA based on the individual signal intensities rela-
tive to background for the co-hybridized samples.
Candidate miRNAs with differential expressions between
the MDA-Exo samples and the MCF7-Exo samples were
selected by a re-ratio p-value ≤0.0001 and at least two-fold
change in at least one comparison (Accession #GSE52802).
Records, which may correspond to questionable miRNAs
according to Chiang et al., [23] or in-house validated
miRNAs were removed from the candidate list. The result-
ing expression profiles of the selected miRNAs wereome-like vesicles. A) MCF-Exo and MDA-Exo were negatively stained
ith higher magnification, the scale bar represents 500 nm. B) Identified
e targets were identified using Mascot protein database. The score is the
p < 0.05).
Table 1 Catalogue of the identified peptide targets commonly expressed in both MCF-Exo and MDA-Exo
Protein name MW (KDa) Gene Average score Sequence






















Tubulin beta chain 49.6 TBB5 258.5
K.LAVNMVPFPR.L
K.EVDEQMLNVQNK.N
Heat shock cognate 71 kDa protein 70.8 HSP7C 252.5
K.DAGTIAGLNVLR.I
K.NQVAMNPTNTVFDAK.R
Glyceraldehyde-3-phosphate dehydrogenase 36 G3P 249.5
R.VVDLMAHMASK.E
K.LISWYDNEFGYSNR.V
Tubulin alpha-1C chain 49.8 TBA1C 223.5
K.DVNAAIATIK.T
K.TIGGGDDSFNTFFSETGAGK.H
Sodium/potassium-transporting ATPase subunit alpha-1 11.2 AT1A1 197
K.TSATWLALSR.I
R.LNIPVSQVNPR.D
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Table 1 Catalogue of the identified peptide targets commonly expressed in both MCF-Exo and MDA-Exo (Continued)
















Myristoylated alanine-rich C-kinase substrate 31.5 MARCS 118
K.EAPAEGEAAEPGSPTAAEGEAASAASSTSSPK.A
K.EELQANGSAPAADKEEPAAAGSGAASPSAAEK.G
Annexin A5 35.9 ANXA5 98
K.VLTEIIASR.T
R.SEIDLFNIR.K
Calmodulin 16.8 CALM 96.5
K.EAFSLFDKDGDGTITTK.E
R.VFDKDGNGYISAAELR.H
MARCKS-related protein 19.5 MRP 90
K.GEGESPPVNGTDEAAGATGDAIEPAPPSQGAEAK.G
R.GDVTAEEAAGASPAK.A
Integrin alpha-2 129.2 ITA2 76 K.TQVGLIQYANNPR.V
Galectin-3-binding protein 65.3 LG3BP 73 R.ASHEEVEGLVEK.I
Histone H1t 22 H1T 60.5 K.ALAAAGYDVEK.N
Alpha-enolase 47.1 ENOA 60.5 R.YISPDQLADLYK.S
Kinesin-like protein KIF12 70.6 KIF12 60 K.LTKLLADSLGGR.G
Elongation factor 1-gamma 50.1 EF1G 57 K.ALIAAQYSGAQVR.V
Peroxiredoxin-1 22.1 PRDX1 50.5
K.ATAVMPDGQFK.D
R.QITVNDLPVGR.S
Ubiquitin-40S ribosomal protein S27a 17.9 RS27A 49.5 K.ESTLHLVLR.L
14-3-3 protein epsilon 29.1 1433E 43.5 K.EAAENSLVAYK.A
The peptide targets were identified using Mascot database. The score is the probability of an overlap between the peptide features and the database
peptides (p < 0.05).
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dimensional hierarchical clustering [25] was applied using
Euclidean Distance and complete linkage method. Also the
miRNAs were quantified using the Universal Reference
(UR) consisting of 954 synthetic miRNAs in equimolar con-
centrations, which enables the cross-referencing of experi-
ments. To discriminate questionable results from relevant
results, the absolute quantification was performed only for
those miRNAs which revealed a signal in the UR sample as
well as in the sample of interest at least 1-fold above aver-
age signal intensities of the background [23].
For the validation of the miRNA array we performed
RT-PCR to assess the miRNA levels of selected miRNA
from the let-7 family using SYBRgreen MasterMix
(Exiqon, Vedbaek, Denmark). Primers were used forLet-7a: ugagguaguagguuguauaguu; Let-7b: ugagguagua
gguugugugguu; Let-7c: ugagguaguagguuguaugguu; Let-
7d: agagguaguagguugcauagu; Let-7e: ugagguaggagguug
uauagu; Let-7f: ugagguaguagauuguauaguu; Let-7i: ugag
guaguaguuugugcugu. Relative expression levels were
calculated based on the expression of three constitutive
(u6, 5 s, snord44) miRNA references. Expression levels of
miRNAs were calculated after subtracting the CT-values of
the endogenous references, and fold change of gene ex-
pression was subsequently calculated using ΔΔCT-method.
Statistical methodology
All data were summarized using descriptive statistics
such as mean and standard deviation. The variance
method was used to compare the mean differences.
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ally. The study hypotheses were tested at 5% level of sig-
nificance throughout the analysis. Estimates of means
and their 95% confidence intervals were calculated. R-
computing software was used to plot the graphs.Results
Isolation of exosome-like vesicles from MCF7 and MDA-
MB 231 cells
The exosome-like vesicles were collected and purified from
the culture supernatants of two breast cancer cell lines,
MDA-MB 231 and MCF-7. The protein assessment of the
exosome-like preparations indicated of quiet similar
amounts of vesicles for both MCF7 (25.594 ± 2.16 μg/ml)
and MDA-MB 231 cells (24.388 ± 3.72 μg/ml). Electron mi-
crographs revealed that the isolated exosome-like particles
consisted of primarily round shaped vesicles (Figure 1A).
Quantitative analysis indicates that MCF-7 derived
exosome-like vesicles (MCF-Exo) and MDA-MB231 de-
rived exosome-like vesicles (MDA-Exo) exhibit relatively
similar size with the diameter ranging from 80 to 200 nm.A B
C
Figure 2 Exosome-like vesicle proteomics analysis. Diagram illustrating
Gene ontology analysis identified proteins in MCF-Exo (A) and MDA-Exo (B
MDA-Exo were grouped according to their putative functions and are show
of Annexin A1, Annexin A2, alpha-enolase, and EpCAM expression in exosoProteomic analysis of exosome-like vesicles derived from
MCF-7 and MDA-MB 231 cells
To profile the protein content of the two types of
exosome-like vesicles, the vesicles were treated with
acetone to precipitate their protein content. Then, 15 μg
of total protein was loaded on SDS-PAGE gel, which
was followed by in-gel trypsin digestion, and was subse-
quently analyzed by LC-MS/MS. The data analysis using
Mascot database has identified proteins and their scores
for both MCF-Exo and MDA-Exo. This analysis identified
59 proteins in MCF-Exo and 88 proteins in MDA-Exo. A
total of 32 and 61 proteins were exclusively detected in
MCF-Exo and MDA-Exo, respectively (Figure 1B and C
and Additional file 1: Tables 1 and Additional file 2:
Table S2). Among the identified proteins, 27 proteins
found to be expressed in both types of vesicles (Table 1).
The ontology of the identified proteins was analyzed using
PANTHER software (Protein Analysis Through Evolution-
ary Relationships). As shown in Figure 2A and B, the de-
termined proteins were grouped and compared between
the two types of vesicles. All proteins were grouped into
15 protein classes including catalytic activity, cell adhesion,the distribution of proteins identified from MCF-Exo and MDA-Exo.
) using PANTHER software. The proteins detected in MCF-Exo and
n by percentage of total identified proteins. C) Western blot analysis
me-like vesicles.
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two types of vesicles identified significant differences in
the expression of extracellular matrix proteins in MCF-
Exo (8.6%) and MDA-Exo (24%). This may explain the
higher metastatic attribute of MDA-MB 231 compared to
MCF-7 cells. While MCF-Exo contains higher nucleic acid
binding and protein binding and protein transport activity,
the MDA-Exo contains proteins with more catalytic activ-
ity. To validate the proteomic data, western blot analysis
was performed for proteins commonly expressed in both
types of exosome-like vesicles (Annexing A2 and alpha-
enolase), and was also performed for exclusive expressionsA B
Figure 3 Differential gene expression in exosome-like vesicles. A) Hie
in each vesicle type. The extent of green (decreased fold change) or red (incr
differential expression of miRNAs. To perform these comparisons, probe sets w
data matrix. The data were grouped by type of exosome-like vesicles and me
identify those miRNAs that were expressed in a statistically significant ma
Bars represent fold change of hybridization signals in MDA-Exo against MCF-E
MDA-Exo and MCF-Exo, respectively. The miRNAs were quantified using the u
experimental data. Then the expression values were compared in two types oof Annexin A1 and EpCAM for MCF-Exo and MDA-Exo,
respectively (Figure 2C).
microRNA analysis
Global miRNA comparison of two types of exosome-like
vesicles was performed to obtain an overview of differ-
ences in miRNA expression patterns that may play a role
in the manifestation of the two breast cancer cell types.
These experiments were performed using miRNA micro-
array (Miltenyi Biotec), and the data were analyzed by
normalization and calculations of sample intensity versus
the Universal Reference, using miRXploreR softwarerarchical clustering was used to display miRNAs differentially expressed
eased fold change) colors is directly proportional to the magnitude of
hose target was not detected in any sample were eliminated from the
mbers of each group were pooled, before a Student’s t-test was used to
nner (P < 0.05). B) miRNA profiles of the MDA-Exo versus MCF-Exo.
xo. Blue and red bars display relatively higher miRNA expressions in
niversal reference in equimolar concentrations and cross referenced with
f exosome-like vesicles (three independent experiments; P < 0.05).
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method [22]. Hierarchical clustering was used to dis-
play miRNAs that are differentially expressed in each
type of exosome-like vesicles (Figure 3A). The quantifi-
cation on miRNAs using cross-referencing of miRNA
signals against universal reference revealed higher
amounts of mir-198, mir-26a, mir-34a and mir-49a
enclosed in MCF-Exo, whereas, several miRNAs includ-
ing mir-130a, mir-328, and mir-149 were more abun-
dant in MDA-Exo (Figure 3B).
Then to validate the microarray data, a group of miR-
NAs (let-7a, mir-328, mir130a, mir-149, mir-602, mir-
92b, and mir-198) was selected for RT-PCR analysis.
The miRNAs were readily detected with relatively high
amounts in both types of vesicles. Comparing the two
types of exosome-like vesicles showed that while MCF-
Exo encloses greater amounts of mir-198, MDA-Exo
contains higher levels of let-7a, mir-328, mir-130a, mir-
149, mir-602, and mir-92b (Figure 4).
Discussion and conclusions
This study reports the characterization of exosome-like
vesicles released from two breast cancer cell lines, MCF-7
and MDA-MB 231. The results of this study are important
when considering circulating exosome-like vesicles for
diagnosis, and assessing the biological significance of the
release of onco-proteins and miRNAs from these vesicles.
This becomes more significant in view of the fact that
exosome-like vesicles can easily enter the circulation and
may possibly affect non-malignant cells. The MCF7 and
MDA-MB 231 cell lines account for a large number of
basic and pre-clinical studies on breast cancer around the
globe [26]. Several studies indicated a possible role of
extracellular vesicles in tumor progression; however, the
exact protein and genetic attributes enclosed in theseFigure 4 Quantitative real-time PCR of miRNAs performed to validate
up-regulation of let-7a, mir-328, mir-130a, mir-149, mir-603, and mir-92b from
(*P < 0.01). miRNA expression values were normalized to three constitutive mvesicles remain to be determined. The circulating vesicles
have been described in patients with various tumors
[8,27,28], suggesting that they may serve as a diagnostic
and prognostic tool. In the context of cancer, the potential
role of tumor-derived extracellular vesicles in tumor
microenvironment and their involvement in cancer pro-
gression must be considered. Detailed interrogation of the
protein dataset revealed a protein signature of exosome-
like vesicles, which may further delineate their biogenesis.
A number of studies have detailed the proteomics [29]
and miRNA profile of MCF-7 [30] and MDA-MB 231
cells [17]. However, the present study is the first report
comparing these two cell lines for their both proteomic
and miRNA profiles. Proteomic analysis identifies several
proteins expressed in both MCF-Exo and MDA-Exo, in-
cluding proteins belonging to the Annexin family. Annex-
ins are calcium-dependent phospholipid-binding proteins
that play an important role in the regulation of cellular
growth and in signal transduction pathways. Histone H4
protein is expressed in both types of exosomes, which has
a crucial role in epigenomic alterations of cells via disturb-
ing normal expression of DNA methyltransferase and his-
tone methyltransferase. This is associated with increased
malignant properties of cancer cells [31]. Calmodulin, a
regulator of Akt pathway is associated with poor prognosis
in breast cancer patients [32], has been identified in both
studied types of exosome-like vesicles. Comparing the
MCF-Exo and MDA-Exo demonstrates a significantly
higher expression of matrix metalloproteinase proteins in
MDA-Exo. This can be related to the enhanced metastatic
characteristics of MDA-MB 231 cells. In contrast, the
MCF-Exo contains higher levels of nucleic acid, protein
binding, and transfer proteins. In addition, the significant
Gene Ontology analysis revealed that several of profiled
miRNAs are related with pathways which may play anthe microarray data. Down-regulation of mir-198 in MCF-Exo and
microarray experiments were validated by quantitative PCR analysis
iRNA references u6, 5 s, snord44 (five independent experiments; P < 0.05).
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ing the miRNAs in MDA-Exo to MCF-Exo showed a
higher expression of tumorigenic mir-130a in MDA-Exo.
it has been shown that mir-130a contribute to tumorigen-
esis of colon cancer by regulating TGB-β/Smad signaling
[33]. MDA-Exo also contains a significant amount of mir-
328, which has been shown to target CD44, reduce cell
adhesion, enhances cell migration, and regulate formation
of capillary structure [34]. In contrast, MCF-Exo contains
higher amounts of mir-301a. The mir-301a over expres-
sion has been implicated as a negative prognostic indica-
tor in lymph node negative (LNN) invasive ductal breast
cancer [35]. MCF-Exo also contains mir-34a, which regu-
lates several genes including p53 [36]. The mir-106b is
found in higher levels in MCF-Eox as well. This miRNA
can promote breast cancer invasion and metastasis by tar-
geting BRMS1 and RB. The mir-106b mediates TGF-β-
induced epithelial-mesenchymal transfer, which is an early
process of tumor metastasis [37].
For the discovery of novel circulatory tumor markers,
proteomics and genomic approaches have been conducted
on blood and tissue samples. However, there are contra-
dictory reports whether profiles of miRNAa and tumor
specific proteins in blood circulation are parallel with tu-
mor’s profiles. The exosomal miRNA signatures originat-
ing from tumor cells have been reported in breast cancer
or lung adenocarcinoma cases [8,38]. It is reasonable to
speculate that these vesicles exert different effects to the
possible acceptor targets. For example, the vesicles po-
tentiate the malignant properties of neighboring neoplas-
tic cells or activate non-malignant cells. Understanding
the communication between the tumor cells and the
extracellular environment through extracellular vesicles is
of great importance. Our data show that extracellular vesi-
cles carry oncogenic proteins and miRNAs, which may
further be applicable for early detection of breast malig-
nancy as well as delineating the possible role of extracellu-
lar vesicles in tumorigenesis and metastasis.
Additional files
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